1592 completed, 621 unknown, 613 recruiting, 411 terminated. 1331 Phase 2, 1085 Phase 1, 720 Not applicable, 228 Phase 3, 86 Early Phase 1.
Follow Pancreatic Neoplasms: new trials by email Literature Review of Pancreatic Neoplasms trials Research Report on Pancreatic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas - Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor | Not applicable | Enrolling by invitation | Ohio State University Comprehensive Cancer Center | 12 | 2027-10-01 | 2026-10-13 |
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC Rintatolimod - Pancreatic Cancer | Phase 2 | Suspended | AIM ImmunoTech Inc. | 90 | 2027-08-01 | 2026-08-19 |
| Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation DN022150+AG( Stage I ）, DN022150+AG（Stage II）, placebo+AG（Stage II） - Pancreatic Cancer, Pancreatic Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 465 | 2027-06-06 | 2026-06-18 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer EF-009 - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Everfront Biotech Co., Ltd. | 30 | 2027-04-01 | 2026-09-11 |
| A Prospective Study of Concurrent Hyperthermia, Chemotherapy and Radiotherapy in Borderline and Locally Advanced Pancreatic Cancer (PANHEAT) Hyperthermia plus neoadjuvant chemotherapy/radiotherapy Arm Description: Hyperthermia plus neoadjuvant chemotherapy (mFOLFIRINOX/nab Paclitaxel) followed by a) surgically resectable: Hyp - Borderline and Locally Advanced Pancreatic Cancer | Not applicable | Not yet recruiting | Fernando Pessoa Canarias University | 60 | 2027-03-31 | 2026-09-24 |
| Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity blood sampling - Pancreatic Cancer | Not yet recruiting | Institut Paoli-Calmettes | 310 | 2027-01-04 | 2026-09-18 | |
| TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2027-01-01 | 2026-08-05 |
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC vilastobart (XTX101), Retifanlimab - Pancreatic Cancer Metastatic | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2027-01-01 | 2026-08-14 |
| A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer MRG004A plus best supportive care, Placebo plus best supportive care - Advanced Pancreatic Cancer | Phase 3 | Not yet recruiting | Lepu Biopharma Co., Ltd. | 231 | 2027-01-01 | 2026-05-15 |
| 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 15 | 2026-12-16 | 2026-05-27 |
| Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant - Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 60 | 2026-12-15 | 2026-10-20 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) Gemcitabine Delivered by Transarterial Microperfusion - Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Vermont | 10 | 2026-12-01 | 2026-03-17 |
| Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) PCX-12 - Pancreatic Adenocarcinoma | Phase 1 | Not yet recruiting | Haoming (Carl) Qiu | 24 | 2026-12-01 | 2026-02-05 |
| Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer H101, Camrelizumab - Pancreatic Cancer | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2025-08-07 |
| EUS-DFI in Solid Pancreatic Lesions Pancreatic Neoplasms, Pancreatic Solid Lesions | Not yet recruiting | Julio Iglesias García | 48 | 2026-12-01 | 2026-08-13 | |
| Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Gemcitabine (1000 mg/m2), Nab-paclitaxel, L-glutamine - Pancreatic Cancer | Phase 2 | Not yet recruiting | Jun Gong, MD | 200 | 2026-12-01 | 2026-10-08 |
| ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Anova Innovation Limited | 84 | 2026-12-01 | 2026-10-23 |
Showing 20 of 3876. Sign in to see all of them.
Colorectal Neoplasms (429) · Stomach Neoplasms (395) · Breast Neoplasms (358) · Neoplasms (325) · Ovarian Neoplasms (296) · Carcinoma, Non-Small-Cell Lung (281) · Lung Neoplasms (275) · Colonic Neoplasms (255) · Esophageal Neoplasms (242) · Neoplasm Metastasis (235) · Prostatic Neoplasms (193) · Liver Neoplasms (181) · Melanoma (162) · Head and Neck Neoplasms (142)
Endocrine System Diseases (3866) · Endocrine Gland Neoplasms (3863) · Digestive System Diseases (3862) · Neoplasms by Site (3860) · Digestive System Neoplasms (3850) · Pancreatic Diseases (3824) · Neoplasms (3551) · Neoplasms by Histologic Type (923) · Gastrointestinal Diseases (835) · Neoplasms, Glandular and Epithelial (808) · Gastrointestinal Neoplasms (737) · Intestinal Diseases (669) · Intestinal Neoplasms (650) · Pathological Conditions, Signs and Symptoms (628) · Colonic Diseases (606)
Gemcitabine (700) · 130-nm albumin-bound paclitaxel (211) · Fluorouracil (200) · Oxaliplatin (182) · Albumin-Bound Paclitaxel (160) · Capecitabine (147) · Leucovorin (140) · Irinotecan (116) · Radiotherapy (98) · pembrolizumab (88) · Taxes (83) · Cisplatin (81) · Erlotinib Hydrochloride (71) · Radiosurgery (71) · Bevacizumab (61)
National Cancer Institute (NCI) (125) · M.D. Anderson Cancer Center (65) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (52) · Memorial Sloan Kettering Cancer Center (51) · Fudan University (50) · Mayo Clinic (40) · Peking Union Medical College Hospital (35) · Washington University School of Medicine (35) · Changhai Hospital (34) · H. Lee Moffitt Cancer Center and Research Institute (34) · Dana-Farber Cancer Institute (28) · Eli Lilly and Company (27) · Massachusetts General Hospital (27) · IRCCS San Raffaele (26) · Ruijin Hospital (24)
United States (1901) · China (574) · France (243) · Italy (219) · Spain (201) · Canada (194) · South Korea (191) · United Kingdom (181) · Germany (175) · Australia (129) · Netherlands (116) · Belgium (109) · Japan (94) · Taiwan (87) · Denmark (75)
Shyam Varadarajulu, MD (12) · Saleh K Saleh, MD (11) · Michele Reni, MD (8) · Dung Le, MD (7) · Vincent Chung (7) · Andrew Ko, MD (6)
PMID 39863139, PMID 37598000, PMID 21561347, PMID 23433878, PMID 24131140, PMID 28733257, PMID 33337539, PMID 15273542, PMID 15855973, PMID 21420083, PMID 23547081, PMID 28040257, PMID 40056080, PMID 42836590, PMID 15908661, PMID 18494054, PMID 18992248, PMID 20620274, PMID 20842054, PMID 21831266, PMID 22321518, PMID 22341257, PMID 22658389, PMID 23229886, PMID 24368638, PMID 24578254, PMID 24840647, PMID 24901360, PMID 24982456, PMID 25512461, PMID 25733127, PMID 26341722, PMID 26422979, PMID 26615328, PMID 26879162, PMID 27275632, PMID 27650271, PMID 28025154, PMID 29119276, PMID 29223478, PMID 29325707, PMID 29508247, PMID 29800971, PMID 29929491, PMID 29941289, PMID 30834048, PMID 31481506, PMID 31654634, PMID 32526235, PMID 32583392
2023 (16), 2016 (15), P30CA006973 (14), P30CA016672 (14), P30CA033572 (14), 2014 (13), 2015 (12), 2017 (12), 2019 (12), 2025 (11), P30CA015083 (11), 2018 (10), P30CA068485 (10), U10CA031946 (9), UM1CA186689 (9)